Smaller prospective trials with heterogeneous patient collectives, one with choline PET imaging [10], one with PSMA ligand PET imaging [25] and one with sodium fluoride (NA-F) PET imaging [11], showed encouraging results for MDT for oligometastatic prostate cancer. This evidence concerns the gene FOLH1 and prostate cancer.